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ABSTRACT 
Objective: The present research work aims to develop a microemulsion loaded sublingual film for rapid absorption of fentanyl citrate in transient 
breakthrough pain.  
Methods: The Fentanyl citrate microemulsion loaded sublingual film was prepared using Capmul MCM C8 (oil), tween 20 (surfactant) and 
propylene glycol (co-surfactant) with different grades of film-forming polymer (HPMC) using a film casting machine. The films were evaluated for in 
vitro disintegration study, tensile strength, folding endurance, content uniformity, drug content, in vitro dissolution, pH, thickness and weight 
variation, scanning electron microscopy, ex vivo permeation study, droplet size, polydispersity index, zeta potential, % moisture content and 
stability study were evaluated. 
Results: The optimized film formulation showed desired mechanical properties (tensile strength of 0.291 kg/cm2
Conclusion: The present study indicated that extend of permeation of fentanyl citrate when added to the sublingual film in microemulsion form 
was around 2.225 folds higher than when added directly to film without microemulsion. The present microemulsion embedded film technology 
could be a promising alternative to conventional drug delivery systems and traditional routes of administration for breakthrough pain management. 
) and a minimum disintegration 
time of 20 s. The optimized sublingual film formulation exhibited 43.16 % of FC microemulsion loading. Morphological study showed the absence of 
drug crystals on the polymeric surface. Permeation studies through goat sublingual mucosa indicated 89% fentanyl citrate release through fentanyl 
citrate microemulsion loaded sublingual film, whereas only 40% fentanyl citrate release was obtained when it was directly added to film without 
microemulsion strategy. 
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INTRODUCTION 
Fentanyl citrate (FC) is a small and potent µ-receptor agonist that is 
given in low doses (100-1000 µg), and lacks the bitter taste 
associated with some other opioids [1, 2]. FC is known to be effective 
in the treatment of breakthrough pain which is estimated in more 
than half of cancer patients [3]. Breakthrough pain in cancer patients 
ranges from 40% to 93%, and these patients suffer an average of 4 
episodes of breakthrough pain per day [4, 5]. For the successful 
treatment of transient breakthrough pain, the analgesic used must 
be fast-acting and provide immediate pain relief. The low oral 
bioavailability of FC limits its therapeutic utility due to metabolism 
by the enzyme CYP3A4 in the gastrointestinal tract as well as first 
passes hepatic clearance [6-8].  
Fentanyl is a highly lipophilic compound (octanol-water partition 
coefficient at pH 7.4 is 816:1) having peak analgesic effects within a 
few minutes of IV administration and a duration of action, after 
small to moderate doses, of 30 to 60 min [9]. But parenteral 
administration of fentanyl is usually unsuitable or inconvenient for 
the patient for the self-management of breakthrough pain, especially 
in the home environment. Fentanyl has therefore been formulated 
for administration by a number of alternative routes including 
transdermal [10], pulmonary [11, 12], oral [13-15], oral 
transmucosal [16-19] and intranasal [20-22]. Sublingual 
administration is noninvasive, and the transmucosal absorption of 
lipophilic drugs is rapid [23-25]. Sublingual fentanyl appears to be 
clinically useful, safe and well tolerated by the patients [26] and 
causes minimal mucosal irritation [19]. Whereas the sublingual 
route offers good bioavailability (57%) and which further can be 
increased by proposed strategy. 
Thus currently there is a need for a sublingual film dosage form that 
provides the desired absorption level of fentanyl. Hence, the 
objective of the current research work was to develop a fast-
dissolving microemulsion (ME) loaded sublingual film of fentanyl 
citrate for transient breakthrough pain. To achieve this objective, 
fentanyl citrate in microemulsion form is incorporated into the 
sublingual film for better sublingual bioavailability. 
MATERIALS AND METHODS  
Materials 
Fentanyl citrate USP was purchased from Rusan Pharma Ltd. Works, 
Ankleshwar, Gujrat. Propylene Glycol was purchased from Shell 
Chemicals, Singapore. Capmul® MCM C8 (Mono/diglycerides of 
caprylic acid) was obtained as a gift sample from ABITEC 
Corporation, Columbus, USA. Monebat®
Methods 
-20 (Polyoxyethylene 20 
sorbitan monolaurate) was obtained as a gift sample from Mohini 
Organics Pvt. Ltd. Malad (West), Mumbai. 
Preparation of fentanyl citrate microemulsion loaded 
sublingual films 
Polymeric ME drug-loaded sublingual film was prepared using film 
casting machine at 1.5 V and wet thickness of 0.50 mm and 
dimensions of film was set at 20 × 22.5 mm and dried immediately. 
Preparation of FC microemulsion and polymeric solutions used to 
make are as follows. Weigh each ingredient accurately as described 
in table 1 to prepare formulations F1 to F3. Initially, FC 
microemulsion was prepared using Capmul MCM C8 (oil), tween 20 
(surfactant) and propylene glycol (co-surfactant) using water 
titration method [27, 28]. In C2 optimized microemulsion, Smix ratio 
was 1:1 (table 1). This resulted into the formation of a clear 
microemulsion and to it calculated quantity of FC was added and 
sonicated for 30 min. Then alpha-tocopherol acetate and BHA (as an 
antioxidant), sucralose (sweetener), sunset yellow (color) and 
orange flavor were added and further sonicated for 20 min to obtain 
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solution A. Separately, HPMC E5, HPMC E15 was dissolved in water 
by continuous stirring and allowed to swell for 60 min to obtain 
solution B.  
Then, FC loaded ME i.e. solution A was mixed with hydrated 
polymeric solution i.e. solution B with continuous stirring on 
mechanical stirrer (Remi motors, Remi Electrotechnik Ltd., Vasai, 
Mumbai, India) for nearly 40 min to obtain a homogeneous mixture 
i.e. solution C. Finally; solution C was cast on the film casting 
machine and allowed to dry at 50 °C for 40 min. On removal from 
the release liner, the film was checked for any imperfections before 
being cut into 20 × 20 mm squares [29]. 
 
Table 1: Composition of C2 ME microemulsion loaded sublingual films on film casting machine 
Ingredients (%) F1 F2 F3 
Fentanyl citrate - - 3.15 
C2 ME Capmul MCM C8 9.35 4.46 4.32 
Tween-20 24.91 11.90 11.52 
PG 12.43 5.94 5.75 
H2O in ME q. s. q. s. q. s. 
HPMC E 5 - 51.62 50.0 
HPMC E 15 48.65 23.33 22.6 
Sucralose 1.62 1.29 1.25 
Orange flavour 1.62 1.29 1.25 
Sunset yellow color 0.05 0.02 0.02 
Alpha tocopherol acetate 0.32 0.15 0.15 
D. M. water q. s. q. s. q. s. 
Total film weight 18.5 38.74 40.00 
 
Development of plain fentanyl citrate sublingual films 
Plain Fentanyl citrate sublingual films were casted on film casting 
machine. The purpose of these films was to be used as control for in 
vitro drug dissolution study and ex vivo drug release study. The 
formulation code and composition of plain fentanyl citrate 
sublingual film was given in table 2. The hydrophilic polymers were 
dissolved in a fixed quantity of distilled water and kept aside for 60 
min for swelling of the polymers. To this polymeric dispersion, the 
weight quantity of fentanyl citrate was added and stirred 
continuously on a mechanical stirrer (Remi motors, Remi 
Electrotechnik Ltd., Vasai, Mumbai, India) for nearly 60 min to 
obtain a homogeneous mixture. Resulting solution was casted on 
film casting machine and allowed to dry at 50 °C for 40 min. On 
removal from the release liner, the film was checked for any 
imperfections before being cut into 20 × 20 mm squares. Obtained 
films were used for the comparative release profile of the drug.  
 
Table 2: Composition of plain fentanyl citrate sublingual films 
Ingredients (%) FC Films 
Fentanyl citrate 4.01 
HPMC E5 63.75 
HPMC E15 28.82 
Sucralose 1.59 
Orange flavor 1.59 
Sunset yellow colour 0.03 
Alpha tocopherol acetate 0.19 
D. M. water q. s. 
 
Characterization of FC microemulsion loaded sublingual film 
In vitro disintegration study  
In vitro disintegration of film was performed as described. Initially, 
the film was carefully clamped from both the side and placed in a 
beaker in such a way that water level should be at half level of the 




The prepared films were subjected for the determination of 
mechanical properties using using LINUX Tensile Tester (model TEN 
MD), LINUX Machine Incorporation, Thane, Maharashtra, India, 
instrument according to the procedure described as follows [30]. 
The films of dimensions 30×5 mm were cut and subjected for the 
analysis. Film specimens with physical defects were discarded. The 
films were carefully placed between the two vertical grips of the 
tester during the test. The movable grip was then driven upward 
with a speed of 30mV/min until the rupture of the film. From the 
recorded load extension profiles, the tensile strength, percent 
elongation at break was calculated. 
Folding endurance 
The folding endurance was determined by repeatedly folding one 
film at the same place without breaking [31]. Folding endurance is 
used to estimate the mechanical property of a film [32]. 
Content uniformity 
Content uniformity of films was determined with the assay of ten 
individual films. Each film was transferred to a 20 ml volumetric flask 
and dissolved and extracted in methanol. Drug extracted in methanol 
was analyzed using high-performance liquid chromatography (HPLC) 
method [33]. Briefly, drug analysis was performed Princeton SPHER-100 
C18 HPLC column (250 mm × 4.6 mm, 5 μ ) with the mobile phase 
consisting of solution A (ammonium acetate solution (1g in 100 ml 
water) and solution B (mixture of methanol, acetonitrile, glacial acetic 
acid) (400:200:0.6); where mixture of solution A and solution B 
(400:600) and pH was adjusted to 6.6±0.1 with glacial acetic acid, used 
as mobile phase at a flow rate of 1.5 ml/min. Sample injection volume 
was 25 μL and FC detection was performed using Shimadzu LC solution 
software at a wavelength of 230 nm. 
Drug content 
Ten films were picked randomly and weighted individually. 10 strips 
(equivalent to 8 mg fentanyl) was weighed and transferred in 100.0 
ml of volumetric flask. About 60.0 ml of water was added and 
sonicated for 20 min with intermediate shaking and volume was 
made upto 100.0 ml with water. This solution was then filtered 
through a 0.45 µm pore size nylon membrane (80 ppm fentanyl) and 
analyzed using HPLC method [33].  
In vitro dissolution 
The in vitro dissolution of the formulations was studied as per the US 
FDA-recommended dissolution methods [34] in 500 ml 25 mmol 
phosphate buffer pH 6.4 at 37.0±0.5 °C using the USP Apparatus I 
(Basket) at 100 rpm. At predetermined time intervals for 30 min, 10 ml 
of aliquots was withdrawn and replaced with an equal volume of fresh 
phosphate buffer to ensure sink condition. Aliquots were then analyzed 
using HPLC method as described in “Content uniformity.” This in vitro 
dissolution study was performed for optimized formulation C2 ME (F3) 
(table 1), developed with proposed strategy of FC microemulsion 
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incorporated into sublingual film. The release profile of C2 ME (F3) 
sublingual film was compared with plain fentanyl citrate sublingual film 
(table 2) in which microemulsion was not added.  
Measurement of pH 
The pH study was carried out by preparing 1.0 % w/v solution of 
�ilm at 25 ̊C±0.5 ̊C. pH measurement was done using pH meter 
(Contech Instruments Ltd., Navi Mumbai, India). In this method pH 
probe was placed in contact with 1.0 % w/v solution of film and the 
pH was recorded [35]. 
Thickness and weight variation 
The thickness of films was measured using a digital micrometer 
screw gage (Mitutoyo, Microvision Calibration Services, Japan). For 
each formulation, three randomly selected films cut into 20 × 20 mm 
were used. Thickness was measured at five different points in the 
films and mean value was expressed [35]. Each film was weighted 
individually on an analytical balance (Shimadzu, Japan) and average 
weight calculated [36].  
Percent loading of FC ME in sublingual film  
The percent loading of FC ME in sublingual film was determined by 
calculating the amount of ME (g) added to the total casting solution 
of hydrated polymers (g). The film has been casted till no more 
evidence of oiliness was observed on the surface of casting plate 
after removal of dried sublingual strips. The percent loading of FC 
ME in sublingual film was calculated from the following equation:  
Percent loading of FC ME in sublingual �ilm
=
 Amt of FC ME added to casting solution (g)
Total weight of casting solution (g)
100 
Scanning electron microscopy (SEM) 
The morphological characteristics of the films were studied using 
SEM. The purpose of the morphological study was to evaluate the 
film samples for the presence of any deformities, microemulsion 
droplets and cracks. The samples were examined in a Phenom G2 
Pro/G2 pure, Eindhoven, Netherlands, Scanning electron microscope 
at an acceleration voltage of 10 kV. 
Ex vivo permeation study 
The ex vivo sublingual permeation of FC through the goat sublingual 
mucosa was performed using a modified Franz glass diffusion cell 
[37]. Goat sublingual mucosa was obtained from the slaughter house 
and mounted between the donor and receptor compartments. The 
developed sublingual film was placed on the smooth surface of 
mucosa by gentle pressing and the compartments were clamped 
together. The donor compartment was moistened with 1 ml of 
distilled water (pH 6.2) and the receptor compartment was filled to 
touch the membrane with distilled water. The fluid motion in the 
receptor compartment was maintained by stirring with a magnetic 
bead at 100 rpm and its temperature was maintained at (37±0.2) °C. 
At predetermined time intervals, a 1 ml sample was withdrawn 
(replaced with fresh medium) and analyzed using HPLC method 
[33]. Data analysis was done to calculate steady-state fluxes (JSS
Droplet size, polydispersity index (PDI) and zeta potential  
). 
Re-dispersion (o/w microemulsion re-dispersed from films) of 
optimized F3 (FC C2 ME) sublingual film was performed to measure 
particle size and PDI using dynamic light scattering (DLS) (Malvern 
Zetasizer ZEN3500, UK) and zeta potential using the nanopartica SZ-
100 (Horiba Scientific Ltd., Japan). Square films with an area of 4.0 
cm2
% Moisture content (Karl Fisher titration method) 
 were placed in 10 ml of de-ionized water. All measurements 
were performed with a scattering angle of 90 ̊ at 25.0 ̊C; after 
diluting the dispersion to an appropriate volume with dispersion 
medium viscosity 0.894 mPa. s. A small-volume disposable zeta cell 
was used for the measurement of electrophoretic mobility (μm/s) 
and it is converted to zeta potential by using software with the help 
of Helmholtz-Smoluchowski equation. 
Compact volumetric KF titrator (Metrohm, 915 KF Ti-touch, Swiss 
made) was used for the determination of water content in the 
sublingual film. Then film sample of 100.0 mg, was added to glass 
container containing sufficient quantity of KF reagent for complete 
standardization and analysis of sample. Water content was 
calculated automatically by the apparatus.  
Stability study 
Stability study was performed at room condition and at 40 ̊ C/75% 
RH for 4 w. Each strip of optimized batch F3 was packed in three 
layered laminated aluminium pouch and ten pouches are packed in a 
carton. After 4 w, the films were evaluated for the physical 
appearance, surface pH and drug content.  
RESULTS AND DISCUSSION 
Optimization of FC microemulsion loaded sublingual film 
formulation 
In the present study FC microemulsion was incorporated into the 
sublingual film and for that ME with Smix
Characterization of FC microemulsion loaded sublingual films 
 ratio of 2:1 was selected 
and quantities of each ME was fixed as per solubility, to incorporate 
1.26 mg dose of FC. Polymers with different viscosities such as 
HPMC E5 and E15 were selected for development of immediate 
release sublingual film. These trial batches were evaluated for its 
film forming capacity. In F1 trial batch the amount of HPMC E15 was 
added to obtain the complete incorporation of microemulsion into 
the sublingual film. The total film weight obtained for F1 trial batch 
was 19.0 mg; which was not suitable for uniformity of weight on film 
casting machine. Hence the film weight was required to be increased 
upto 40.0 mg/film. Hence in further trials F2 and F3, HPMC E5 was 
added along with HPMC E15 to obtained the required film weight on 
film casting machine. Optimized trial batch F3 contains 50.0% of 
HPMC E5 and 22.6% of HPMC E15, which was sufficient to completely 
incorporate C2 microemulsion into the sublingual film and oiliness 
was not observed on the surface of the polyethylene base sheet after 
removal of the sublingual film. Uniformity of weight on film casting 
machine was obtained for this optimized batch (F3) and also exhibited 
complete % loading of C2 ME in F3 sublingual film.  
Physicochemical characteristics of the sublingual film 
The physicochemical properties of the ME-loaded sublingual film 
formulations are shown in table 3. A weight variation value (mg) of 
optimized film was in the range of 41.0-44.0 mg. The average 
thickness of films ranged from 0.125 to 0.130 mm. Thus there was 
proportional gain in weight of films with that of an increase in the 
thickness of films. The optimized sublingual film formulation i.e. FC 
C2 ME sublingual film (F3) showed the value of folding 
endurance>20 (table 3). This value is desirable because it would not 
allow easy dislocation of the films from the site of application or 
breaking of film during administration.  
The pH values of optimized films indicate that it will not produce 
any local irritation upon contact with the sublingual mucosa, as it is 
in the range of salivary pH (6.0–7.0) [38]. Disintegration time of 
optimized sublingual film formulation was found to disintegrate in 
less than 30 sec and has sufficient mechanical strength to bear stress 
during transport and administration of the films. 
 
Table 3: Physiochemical characteristics of optimized 
microemulsion loaded Fentanyl citrate sublingual film 
Evaluation parameters F3 (FC C2 ME) 
Thickness (mm) 0.13±1.02 
Weight (mg) 42.4±0.27 
Folding endurance 23.0±0.82 
pH at 25 ̊ C 6.8±0.08 
Tensile strength (kg/cm2 0.291 ) 
% Elongation at break (%) 2.4 
Disintegration time (sec) 19.64±0.82 
Microemulsion loading (%) 43.16 
Drug content (%) 105.0 ±0.07 
 Note: Date given in mean±SD, where n =3 
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In vitro dissolution study 
FC C2 ME sublingual film (F3) showed highest drug release of 98% 
within 5 min; whereas plain FC sublingual film showed relatively less 
amount of drug release of 45% within 5 min (fig. 1.). This exhibited that 
the proposed strategy of ME incorporated sublingual film reduces the 
particle size by forming o/w type of ME droplets, helps in increasing the 
surface area and, hence, modulates the drug release with a faster rate as 
compared to the release rate of plain FC sublingual film.  
Key attributing factor for differential dissolution profile of C2 ME 
incorporated fentanyl citrate sublingual film (F3) was due to higher 
solubility of fentanyl in co-surfactant i.e. propylene glycol and 
surfactant i.e. tween 20 present in Smix 
Hence FC C2 ME sublingual film (F3) was considered as an 
optimized formulation based on its in vitro dissolution profile and 
further evaluated for SEM studies, content uniformity, droplet size, 
PDI, ZP and ex vivo permeation study using goat sublingual mucosa.  




Fig. 1: In vitro release profile of fentanyl citrate through FC C2 ME 
sublingual film (F3) and plain fentanyl citrate sublingual film 
Content uniformity 
Scanning electron microscopy (SEM) 
The content uniformity of optimized FC C2 ME sublingual film (F3) 
was found to be within the acceptance criteria. The % RSD was 
observed to be less than 2% which indicates uniformity of content. 
SEM images of FC C2 ME (F3) and placebo film developed without 
the addition of microemulsion was shown in fig. 2 and 3. Well 
dispersed FC microemulsion was obtained in F3, whereas 
microemulsion droplets were not observed in the placebo films 
developed without the addition of microemulsion. SEM images of 
vaccum oven-dried microemulsion incorporated film showed 
spherical-shaped nanoparticles embedded in the polymeric matrix.  
 
 
Fig. 2: Scanning electron microphotograph of fentanyl citrate 
microemulsion loaded sublingual film FC C2 ME (F3) 
 
Fig. 3: Scanning electron microphotograph of the placebo 
sublingual film without the addition of fentanyl citrate 
microemulsion 
 
Ex vivo permeation study 
Permeation studies through goat sublingual mucosa indicated that 
the % cumulative release of fentanyl citrate from FC C2 ME 
sublingual film (F3) was 89% and plain FC sublingual film was 40%, 
respectively. This indicates that the extent of permeation of fentanyl 
citrate from F3 was around 2.225 folds higher than that of plain 
fentanyl citrate sublingual film (Fig.4.). Steady-state flux (Jss , µgcm-
2h-1) was calculated and found 35.286 µgcm-2h-1 for FC C2 ME 
sublingual film (F3) and 17.242 µgcm-2h-1
 
for plain fentanyl citrate 
sublingual film. This evidenced an enhanced permeation of FC when 
incorporated in microemulsion form in the sublingual film than over 




4: Ex vivo release profile of fentanyl citrate through FC C2 
ME sublingual film (F3) and plain fentanyl citrate sublingual 
film 
Droplet size and polydispersity index (PDI) 
Droplet size of optimized F3 (FC C2) microemulsion obtained after 
re-dispersion of the sublingual film was 123.5 nm and PDI was 
0.313, which confirmed narrow size distribution of oil droplets (fig. 
5.) [39,40]. The increased particle size of FC C2 microemulsion after 
re-dispersion from sublingual film was maybe due to covering of the 
embedded microemulsion with polymeric matrix of sublingual film. 
Zeta potential measurements  
Zeta potential of microemulsion present in optimized FC C2 ME 
sublingual film (F3) obtained after re-dispersion of the film was 13.1 
mV. Despite the low ZP value, the system remains stable [41]. The 
graph of intensity (a. u.) vs ZP (mV) of C2 ME obtained after re-
dispersion from the sublingual film was exhibited in the fig. 6. 
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Fig. 5: Particle size distribution plot of optimized F3 (FC C2 ME) sublingual film 
 
 
Fig. 6: Zeta potential plot of optimized F3 (FC C2 ME) sublingual film 
 
 
Fig. 7: Karl fischer titration curve for optimized F3 (FC C2 ME) sublingual film 
 
% Moisture content (Karl Fisher titration method)  
The water content of the optimized F3 (FC C2 ME) sublingual film 
was found to be 3.67 % and its Karl Fischer titration curve graph 
was shown in fig. 7. 
Stability study 
The stability study of film formulations was carried out at room 
condition and at 40 ̊ C/75% RH for a period of one month. No change 
was observed in the appearance and flexibility of film. The drug content 
and surface pH was found to be almost constant for up to one month. 
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CONCLUSION 
Two processes, namely, preparation of fentanyl citrate microemulsion 
and their incorporation in sublingual film formulation was integrated 
successfully. SEM studies revealed that spherical o/w microemulsion 
droplets of fentanyl citrate were incorporated in the polymeric matrix of 
sublingual film. It can be revealed from in vitro dissolution and ex vivo 
permeation studies through goat sublingual mucosa that FC 
microemulsion-incorporated sublingual film has enhanced the release 
rate of drug over the plain fentanyl citrate sublingual film. Hence, the 
present study concludes that the fast-acting fentanyl citrate 
microemulsion-incorporated sublingual film is a promising alternative to 
conventional drug delivery systems and a traditional route of 
administration for breakthrough pain management.  
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